Table 3

Univariate and multivariate overall survival analyses
    Characteristic
    Hazard ratio (95% CI)
    P- value
EGFR positive vs EGFR negative 0.91 (0.66 to 1.16) .464
Age >65 vs ≤65 1.04 (0.80 to 1.29) .747
ECOG performance status 2–3 vs 0-1 2.13 (1.66 to 2.60) .002
Therapy with 2- drug vs 3- drug combination 0.82 (0.58 to 1.07) .117
gastroesophageal junction vs Stomach 0.69 (0.40 to 0.97) .009
recurrent disease vs Stage IV at diagnosis 0.84 (0.50 to 1.18) .326
Male vs female 0.92 (0.67 to 1.17) .512
Liver metastasis, yes vs no 1.19 (0.95 to 1.44) .163
Peritoneal metastasis, yes vs no 1.26 (1.00 to 1.52) .079
Intestinal vs diffuse/mixed 0.90 (0.63 to 1.16) .43
Multivariate Overall Survival Analysis
    Characteristic
    Hazard ratio (95% CI)
    P- value
EGFR positive vs EGFR negative 0.85 (0.57 to 1.13) .247
Age >65 vs ≤65 1.16 (0.88 to 1.45) .299
Therapy with 2- drug vs 3- drug combination 0.71 (0.39 to 0.97) .033
gastroesophageal junction vs Stomach 0.78 (0.43 to 1.14) .176
recurrent disease vs Stage IV at diagnosis 0.71 (0.33 to 1.10) .087
Male vs female 1.01 (0.71 to 1.30) .959
Intestinal vs. diffuse/mixed 0.9 (0.59 to 1.22) .517

a Univariate Overall Survival Analysis.

Atmaca et al.

Atmaca et al. BMC Cancer 2012 12:524   doi:10.1186/1471-2407-12-524

Open Data